TDTim Johannes Adrianus Dekker

Tim Johannes Adrianus Dekker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tim Johannes Adrianus Dekker has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tirzepatide Once Weekly for the Treatment of Obesity

    by Tim J A Dekker

    To the Editor: Jastreboff et al. (July 21 issue)1 report a placebo-adjusted weight reduction of 11.9 to 17.8 percentage points among patients with obesity who received tirzepatide, as assessed in the SURMOUNT-1 trial. All the patients were also offered lifestyle interventions. After 72 weeks, weight loss in the placebo group amounted to a mere 3.1% of body mass. The findings in the placebo group were similar to those in the STEP 1 trial of once-weekly semaglutide,2 which showed a 2.4% weight reduction at 68 weeks. However, the placebo-group results in these two trials were strikingly lower than those in previously . . .


  • Oncogene Up-Regulation after Hypomethylating Therapy

    by Tim J A Dekker

    To the Editor: Liu et al. (May 26 issue)1 describe the up-regulation of SALL4 during treatment with hypomethylating agents in patients with myelodysplastic syndrome. The authors interpreted the poor prognosis associated with SALL4 up-regulation as a sign that it is involved in disease progression and might be a target for therapy. Although the authors convincingly demonstrate the up-regulation of SALL4, the functional consequences of this up-regulation were not investigated. Methylation loss is a very common occurrence in patients with acute myeloid leukemia.2 It is therefore likely that during the progression of myelodysplastic syndrome to acute myeloid leukemia many genes other . . .

  • Open Access

    Tumor‐stroma ratio is associated with Miller‐Payne score and pathological response to neoadjuvant chemotherapy in HER2‐negative early breast cancer

    by Sophie C. Hagenaars, Stefanie de Groot, Danielle Cohen, Tim J. A. Dekker, Ayoub Charehbili, Elma Meershoek‐Klein Kranenbarg, Marjolijn Duijm‐De Carpentier, Hanno Pijl, Hein Putter, Rob A. E. M. Tollenaar, et al.

    The tumor‐stroma ratio (TSR) has proven to be a strong prognostic factor in breast cancer, demonstrating better survival for patients with stroma‐low tumors. Since the role of the TSR as a predictive marker for neoadjuvant chemotherapy outcome is yet unknown, this association was evaluated for HER2‐negative breast cancer in the prospective DIRECT and NEOZOTAC trials. The TSR was assessed on 375 hematoxylin and eosin‐stained sections of pre‐treatment biopsies. Associations between the TSR and chemotherapy response according to the Miller‐Payne (MP) grading system, and between the TSR and pathological response were examined using Pearson's chi‐square, Cochran‐Armitage test for trend and regression analyses. A stroma‐low tumor prior to neoadjuvant chemotherapy was significantly associated with a higher MP score (P = .005). This relationship remained significant in the estrogen receptor (ER)‐negative subgroup (P = .047). The univariable odds ratio (OR) of a stroma‐low tumor on pathological complete response (pCR) was 2.46 (95% CI 1.34‐4.51, P = .004), which attenuated to 1.90 (95% CI 0.85‐4.25, P = .119) after adjustment for relevant prognostic factors. Subgroup analyses revealed an OR of 5.91 in univariable analyses for ER‐negativity (95% CI 1.19‐29.48, P = .030) and 1.48 for ER‐positivity (95% CI 0.73‐3.01, P = .281). In conclusion, a low amount of stroma on pre‐treatment biopsies is associated with a higher MP score and pCR rate. Therefore, the TSR is a promising biomarker in predicting neoadjuvant treatment outcome. Incorporating this parameter in routine pathological diagnostics could be worthwhile to prevent overtreatment and undertreatment.


  • Safety of Anti-PD-L1 Inhibition in HIV-1-Infected Patients With Cancer

    by Tim Johannes Adrianus Dekker

    To the Editor In their Brief Report in JAMA Oncology, Gonzalez-Cao et al1 sought to evaluate the safety of durvalumab in HIV-1–infected patients with advanced cancer. The authors cite immune reconstitution inflammatory syndrome (IRIS) as a safety concern for this patient population. Although theoretically conceivable, the occurrence of IRIS when starting checkpoint inhibition in HIV-1–infected patients has thus far been entirely a hypothetical concern. With the DURVAST study results, the authors conclude that treatment with durvalumab is safe.1 Whether their claim extends to all HIV-1–infected patients with cancer is unknown. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.

    • 12 October 2020
      • Vol. 164

    [Nitrofurantoin for uncomplicated urinary tract infections in men: should it be the first choice?]

    by Tim J A Dekker, Anouk E Muller, Luc B S Gelinck

    Nitrofurantoin is a commonly prescribed antibiotic for uncomplicated urinary tract infections. The Dutch College of General Practitioners guideline recommends the use of this drug for the treatment of uncomplicated urinary tract infections in both male and female patients. Treatment with nitrofurantoin has several advantages. Resistance to this antibiotic is low and does not increase in the hospitalized patient population. Treatment with nitrofurantoin is generally well-tolerated. However, two independent studies estimated that approximately 27% of male patients are undertreated with nitrofurantoin. The main downside of nitrofurantoin is the low blood concentration that leads to insufficient tissue penetration. There is little evidence on how often prostatic tissues are involved in male urinary tract infections. Unrecognized tissue involvement can lead to breakthrough urinary tract infections despite nitrofurantoin treatment. Because of this, the safety of nitrofurantoin for male patients is unknown and treatment with this antibiotic should be administered with caution.

  • Open Access

    Risk of COVID-19 in Patients With Cancer

    by Tim Johannes Adrianus Dekker

    To the Editor In their article in JAMA Oncology, Yu et al reported an increased incidence of coronavirus disease 2019 (COVID-19) in patients with cancer compare


  • Therapy for HER2-Positive Metastatic Breast Cancer

    by Tim J. A. Dekker

    To the Editor: Murthy et al. (Feb. 13 issue)1 have shown that tucatinib prolongs survival among patients who have previously received treatment for human epidermal growth factor receptor 2 (HER2)–positive breast cancer. Its activity in patients with brain metastases is encouraging. The combination of tucatinib and capecitabine as agents with central nervous system (CNS) activity, paired with trastuzumab for extracranial control, is appealing, especially given its acceptable safety profile. To fully evaluate tucatinib, measures in addition to overall survival are essential. The mainstay of treatment for cerebral metastases is still radiotherapy.2 Given that the majority of patients had already been . . .


  • Fulvestrant plus capivasertib for metastatic breast cancer

    by Tim Johannes Adrianus Dekker